{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T23:14:27Z","timestamp":1787354067293,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Paclitaxel (PTX) is one of the most common chemotherapeutic drugs for treating breast cancer (BC), but resistance to PTX chemotherapy remains the major cause of treatment failure in BC patients. Our previous studies demonstrated that BRD7 participates in the paclitaxel-mediated chemotherapy sensitization and inhibits the malignant progression of breast cancer. Furthermore, TRIM25 was screened by IP-MS as a potential E3 ubiquitin ligase interacting with BRD7. Nevertheless, the functions and mechanisms of TRIM25 in the malignant progression of breast cancer and PTX resistance, as well as its regulatory relationship with BRD7, are still not clear. Our investigation revealed that TRIM25 effectively promoted cell proliferation, cell cycle progression, and paclitaxel chemoresistance of BC cells. Mechanistically, TRIM25 interacted with BRD7, and the PRYSPRY region of TRIM25 bond to the N-terminal region of BRD7. Additionally, TRIM25 decreased the protein stability of BRD7 through the ubiquitin proteasome pathway by increasing the K48-linked ubiquitination of BRD7 at the K119 site, and then activated the YB1\/Bcl-2 signal axis, thus mediating malignant progression and PTX resistance of breast cancer. We further demonstrated that restoration of BRD7 rescued the inhibitory effect of TRIM25 knockdown on the malignant progression and PTX resistance of BC cells. Furthermore, high expression of TRIM25 was found in clinical breast cancer tissues compared to noncancerous breast tissues, which was positively associated with poor prognosis in BC patients. The expression of TRIM25 was negatively correlated with BRD7 expression, and the combined expression of TRIM25 and BRD7 might be a potential molecular marker for the prediction of malignant progression and prognosis of breast cancer. Our findings demonstrate that targeting the TRIM25\/BRD7\/YB1\/Bcl-2 signal axis might be a potential therapeutic strategy for the treatment of breast cancer.<\/jats:p>","DOI":"10.1038\/s41419-025-08140-8","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T15:11:52Z","timestamp":1764342712000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["TRIM25 degrades BRD7 protein stability through the ubiquitin proteasome pathway to promote breast cancer progression and paclitaxel resistance by activating YB1\/Bcl-2 transcription axis"],"prefix":"10.1038","volume":"16","author":[{"given":"Changning","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengna","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lemei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zubing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhen","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1486-9909","authenticated-orcid":false,"given":"Songqing","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1635-8173","authenticated-orcid":false,"given":"Wei","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5794-4975","authenticated-orcid":false,"given":"Faqing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4938-5397","authenticated-orcid":false,"given":"Ming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"8140_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer Statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"8140_CR2","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s11427-023-2460-0","volume":"67","author":"X Chen","year":"2024","unstructured":"Chen X, Wu W, Jeong JH, Rokavec M, Wei R, Feng S, et al. Cytokines-activated nuclear IKKalpha-FAT10 pathway induces breast cancer tamoxifen-resistance. Sci China Life Sci. 2024;67:1413\u201326.","journal-title":"Sci China Life Sci"},{"key":"8140_CR3","doi-asserted-by":"crossref","unstructured":"Abu Samaan TM, Samec M, Liskova A, Kubatka P, Busselberg D. Paclitaxel\u2019s mechanistic and clinical effects on breast cancer. Biomolecules. 2019;9:789.","DOI":"10.3390\/biom9120789"},{"key":"8140_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1634\/theoncologist.9-suppl_2-24","volume":"9","author":"J Crown","year":"2004","unstructured":"Crown J, O\u2019Leary M, Ooi WS. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist. 2004;9:24\u201332.","journal-title":"Oncologist"},{"key":"8140_CR5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41556-018-0256-3","volume":"21","author":"I Keklikoglou","year":"2019","unstructured":"Keklikoglou I, Cianciaruso C, Guc E, Squadrito ML, Spring LM, Tazzyman S, et al. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nat Cell Biol. 2019;21:190\u2013202.","journal-title":"Nat Cell Biol"},{"key":"8140_CR6","doi-asserted-by":"publisher","first-page":"32254","DOI":"10.1074\/jbc.M806061200","volume":"283","author":"MD Kaeser","year":"2008","unstructured":"Kaeser MD, Aslanian A, Dong MQ, Yates JR 3rd, Emerson BM. BRD7, a novel PBAF-specific SWI\/SNF subunit, is required for target gene activation and repression in embryonic stem cells. J Biol Chem. 2008;283:32254\u201363.","journal-title":"J Biol Chem"},{"key":"8140_CR7","first-page":"1487","volume":"41","author":"J Ma","year":"2019","unstructured":"Ma J, Niu W, Wang X, Zhou Y, Wang H, Liu F, et al. Bromodomain\u2011containing protein 7 sensitizes breast cancer cells to paclitaxel by activating Bcl2\u2011antagonist\/killer protein. Oncol Rep. 2019;41:1487\u201396.","journal-title":"Oncol Rep"},{"key":"8140_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13046-019-1493-4","volume":"39","author":"W Niu","year":"2020","unstructured":"Niu W, Luo Y, Zhou Y, Li M, Wu C, Duan Y, et al. BRD7 suppresses invasion and metastasis in breast cancer by negatively regulating YB1-induced epithelial-mesenchymal transition. J Exp Clin Cancer Res. 2020;39:30.","journal-title":"J Exp Clin Cancer Res"},{"key":"8140_CR9","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.7150\/jca.67447","volume":"13","author":"Y Luo","year":"2022","unstructured":"Luo Y, Wang X, Niu W, Zhou Y, Li M, Ma J, et al. BRD7 stabilizes P53 via Dephosphorylation of MDM2 to inhibit tumor growth in breast cancer harboring Wild-type P53. J Cancer. 2022;13:1436\u201348.","journal-title":"J Cancer"},{"key":"8140_CR10","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1074\/mcp.O114.044792","volume":"14","author":"Z Xiao","year":"2015","unstructured":"Xiao Z, Chang JG, Hendriks IA, Sigurethsson JO, Olsen JV, Vertegaal AC. System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability. Mol Cell Proteom. 2015;14:1419\u201334.","journal-title":"Mol Cell Proteom"},{"key":"8140_CR11","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cell.2006.09.026","volume":"127","author":"JV Olsen","year":"2006","unstructured":"Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell. 2006;127:635\u201348.","journal-title":"Cell"},{"key":"8140_CR12","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s13402-024-00981-3","volume":"47","author":"C Xue","year":"2024","unstructured":"Xue C, Meng H, Niu W, Li M, Wei J, Chen S, et al. TRIM28 promotes tumor growth and metastasis in breast cancer by targeting the BRD7 protein for ubiquitination and degradation. Cell Oncol. 2024;47:1973\u201393.","journal-title":"Cell Oncol"},{"key":"8140_CR13","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3389\/fimmu.2017.01187","volume":"8","author":"M Martin-Vicente","year":"2017","unstructured":"Martin-Vicente M, Medrano LM, Resino S, Garcia-Sastre A, Martinez I. TRIM25 in the regulation of the antiviral innate immunity. Front Immunol. 2017;8:1187.","journal-title":"Front Immunol"},{"key":"8140_CR14","doi-asserted-by":"publisher","first-page":"e1588","DOI":"10.1002\/wrna.1588","volume":"11","author":"NR Choudhury","year":"2020","unstructured":"Choudhury NR, Heikel G, Michlewski G. TRIM25 and its emerging RNA-binding roles in antiviral defense. Wiley Interdiscip Rev RNA. 2020;11:e1588.","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"8140_CR15","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1042\/BST20160077","volume":"44","author":"G Heikel","year":"2016","unstructured":"Heikel G, Choudhury NR, Michlewski G. The role of Trim25 in development, disease and RNA metabolism. Biochem Soc Trans. 2016;44:1045\u201350.","journal-title":"Biochem Soc Trans"},{"key":"8140_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1177\/1533034615595903","volume":"15","author":"Y Qin","year":"2016","unstructured":"Qin Y, Cui H, Zhang H. Overexpression of TRIM25 in lung cancer regulates tumor cell progression. Technol Cancer Res Treat. 2016;15:707\u201315.","journal-title":"Technol Cancer Res Treat"},{"key":"8140_CR17","doi-asserted-by":"crossref","unstructured":"Nasrullah U, Haeussler K, Biyanee A, Wittig I, Pfeilschifter J, Eberhardt W Identification of TRIM25 as a negative regulator of Caspase-2 Expression reveals a novel target for sensitizing colon carcinoma cells to intrinsic apoptosis. Cells. 2019;8:1622.","DOI":"10.3390\/cells8121622"},{"key":"8140_CR18","doi-asserted-by":"crossref","unstructured":"Zheng B, Qian F, Wang X, Wang Y, Zhou B, Fang L. Neddylation activated TRIM25 desensitizes triple-negative breast cancer to paclitaxel via TFEB-mediated autophagy. J Exp Clin Cancer Res. 2024;43:177.","DOI":"10.1186\/s13046-024-03085-w"},{"key":"8140_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13046-024-02964-6","volume":"43","author":"Y Chen","year":"2024","unstructured":"Chen Y, Xu X, Ding K, Tang T, Cai F, Zhang H, et al. TRIM25 promotes glioblastoma cell growth and invasion via regulation of the PRMT1\/c-MYC pathway by targeting the splicing factor NONO. J Exp Clin Cancer Res. 2024;43:39.","journal-title":"J Exp Clin Cancer Res"},{"key":"8140_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03734-4","volume":"12","author":"S Zhou","year":"2021","unstructured":"Zhou S, Peng J, Xiao L, Zhou C, Fang Y, Ou Q, et al. TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability. Cell Death Dis. 2021;12:463.","journal-title":"Cell Death Dis"},{"key":"8140_CR21","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.1158\/0008-5472.CAN-05-3561","volume":"66","author":"J Wu","year":"2006","unstructured":"Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E, et al. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res. 2006;66:4872\u20139.","journal-title":"Cancer Res"},{"key":"8140_CR22","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/s41418-021-00920-x","volume":"29","author":"Jiang","year":"2022","unstructured":"Jiang, Qiu D, Peng T, Li J, Tala S, Ren W, et al. YB-1 is a positive regulator of KLF5 transcription factor in basal-like breast cancer. Cell Death Differ. 2022;29:1283\u201395.","journal-title":"Cell Death Differ"},{"key":"8140_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ccr.2009.04.006","volume":"15","author":"G Mouneimne","year":"2009","unstructured":"Mouneimne G, Brugge JS. YB-1 translational control of epithelial-mesenchyme transition. Cancer Cell. 2009;15:357\u20139.","journal-title":"Cancer Cell"},{"key":"8140_CR24","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41580-023-00629-4","volume":"24","author":"PE Czabotar","year":"2023","unstructured":"Czabotar PE, Garcia-Saez AJ. Mechanisms of BCL-2 family proteins in mitochondrial apoptosis. Nat Rev Mol Cell Bio. 2023;24:732\u201348.","journal-title":"Nat Rev Mol Cell Bio"},{"key":"8140_CR25","first-page":"313","volume":"34","author":"Y Tabuchi","year":"2009","unstructured":"Tabuchi Y, Matsuoka J, Gunduz M, Imada T, Ono R, Ito M, et al. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Int J Oncol. 2009;34:313\u20139.","journal-title":"Int J Oncol"},{"key":"8140_CR26","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1158\/1078-0432.CCR-05-2719","volume":"12","author":"GM Callagy","year":"2006","unstructured":"Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, et al. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res. 2006;12:2468\u201375.","journal-title":"Clin Cancer Res"},{"key":"8140_CR27","first-page":"1253","volume":"56","author":"S Haldar","year":"1996","unstructured":"Haldar S, Chintapalli J, Croce CM. Taxol induces Bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 1996;56:1253\u20135.","journal-title":"Cancer Res"},{"key":"8140_CR28","doi-asserted-by":"crossref","unstructured":"Zhao R, Liu Y, Wu C, Li M, Wei Y, Niu W, et al. BRD7 Promotes cell proliferation and tumor growth through stabilization of c-Myc in colorectal cancer. Front Cell Dev Biol. 2021;9:659392.","DOI":"10.3389\/fcell.2021.659392"},{"key":"8140_CR29","doi-asserted-by":"crossref","unstructured":"Stiekema M, Ramaekers FCS, Kapsokalyvas D, van Zandvoort M, Veltrop RJA, Broers JLV. super-resolution imaging of the A- and B-Type Lamin networks: a comparative study of different fluorescence labeling procedures. Int J Mol Sci. 2021;22:10194.","DOI":"10.3390\/ijms221910194"},{"key":"8140_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13024-015-0065-0","volume":"10","author":"CE O\u2019Brien","year":"2015","unstructured":"O\u2019Brien CE, Bonanno L, Zhang H, Wyss-Coray T. Beclin 1 regulates neuronal transforming growth factor-beta signaling by mediating recycling of the type I receptor ALK5. Mol Neurodegener. 2015;10:69.","journal-title":"Mol Neurodegener"},{"key":"8140_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05632-3","volume":"14","author":"M Li","year":"2023","unstructured":"Li M, Wei Y, Liu Y, Wei J, Zhou X, Duan Y, et al. BRD7 inhibits enhancer activity and expression of BIRC2 to suppress tumor growth and metastasis in nasopharyngeal carcinoma. Cell Death Dis. 2023;14:121.","journal-title":"Cell Death Dis"},{"key":"8140_CR32","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.7150\/ijbs.100833","volume":"20","author":"M Li","year":"2024","unstructured":"Li M, Wei J, Xue C, Chen S, Zhou X, Zheng L, et al. BRD7 enhances the radiosensitivity of nasopharyngeal carcinoma cells by negatively regulating USP5\/METTL3 axis-mediated homologous recombination repair. Int J Biol Sci. 2024;20:6130\u201345.","journal-title":"Int J Biol Sci"},{"key":"8140_CR33","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41401-021-00662-z","volume":"43","author":"YM He","year":"2022","unstructured":"He YM, Zhou XM, Jiang SY, Zhang ZB, Cao BY, Liu JB, et al. TRIM25 activates AKT\/mTOR by inhibiting PTEN via K63-linked polyubiquitination in non-small cell lung cancer. Acta Pharm Sin. 2022;43:681\u201391.","journal-title":"Acta Pharm Sin"},{"key":"8140_CR34","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/iub.1661","volume":"69","author":"HL Zang","year":"2017","unstructured":"Zang HL, Ren SN, Cao H, Tian XF. The ubiquitin ligase TRIM25 inhibits hepatocellular carcinoma progression by targeting metastasis-associated 1 protein. IUBMB Life. 2017;69:795\u2013801.","journal-title":"IUBMB Life"},{"key":"8140_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14190-2","volume":"11","author":"Y Liu","year":"2020","unstructured":"Liu Y, Tao S, Liao L, Li Y, Li H, Li Z, et al. TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway. Nat Commun. 2020;11:348.","journal-title":"Nat Commun"},{"key":"8140_CR36","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ygyno.2005.07.103","volume":"99","author":"M Sakuma","year":"2005","unstructured":"Sakuma M, Akahira J, Suzuki T, Inoue S, Ito K, Moriya T, et al. Expression of estrogen-responsive finger protein (Efp) is associated with advanced disease in human epithelial ovarian cancer. Gynecol Oncol. 2005;99:664\u201370.","journal-title":"Gynecol Oncol"},{"key":"8140_CR37","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.celrep.2017.07.052","volume":"20","author":"LA Walsh","year":"2017","unstructured":"Walsh LA, Alvarez MJ, Sabio EY, Reyngold M, Makarov V, Mukherjee S, et al. An integrated systems biology approach identifies TRIM25 as a key determinant of breast cancer metastasis. Cell Rep. 2017;20:1623\u201340.","journal-title":"Cell Rep"},{"key":"8140_CR38","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1032>3.0.CO;2-Y","volume":"91","author":"SD Thomson","year":"2001","unstructured":"Thomson SD, Ali S, Pickles L, Taylor J, Pace PE, Lymboura M, et al. Analysis of estrogen-responsive finger protein expression in benign and malignant human breast. Int J Cancer. 2001;91:152\u20138.","journal-title":"Int J Cancer"},{"key":"8140_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.bbrc.2022.07.071","volume":"624","author":"W Sato","year":"2022","unstructured":"Sato W, Ikeda K, Gotoh N, Inoue S, Horie K. Efp promotes growth of triple-negative breast cancer cells. Biochem Biophys Res Commun. 2022;624:81\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"8140_CR40","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/cgt.2010.19","volume":"17","author":"K Ueyama","year":"2010","unstructured":"Ueyama K, Ikeda K, Sato W, Nakasato N, Horie-Inoue K, Takeda S, et al. Knockdown of Efp by DNA-modified small interfering RNA inhibits breast cancer cell proliferation and in vivo tumor growth. Cancer Gene Ther. 2010;17:624\u201332.","journal-title":"Cancer Gene Ther"},{"key":"8140_CR41","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1042\/BJ20111890","volume":"444","author":"XY Dong","year":"2012","unstructured":"Dong XY, Fu X, Fan S, Guo P, Su D, Dong JT. Oestrogen causes ATBF1 protein degradation through the oestrogen-responsive E3 ubiquitin ligase EFP. Biochem J. 2012;444:581\u201390.","journal-title":"Biochem J"},{"key":"8140_CR42","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nature00826","volume":"417","author":"T Urano","year":"2002","unstructured":"Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, Muramatsu M, et al. Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature. 2002;417:871\u20135.","journal-title":"Nature"},{"key":"8140_CR43","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.bbrc.2017.08.151","volume":"493","author":"X Qin","year":"2017","unstructured":"Qin X, Qiu F, Zou Z. TRIM25 is associated with cisplatin resistance in non-small-cell lung carcinoma A549 cell line via downregulation of 14-3-3s. Biochem Biophys Res Commun. 2017;493:568\u201372.","journal-title":"Biochem Biophys Res Commun"},{"key":"8140_CR44","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1038\/s41388-017-0095-x","volume":"37","author":"KI Takayama","year":"2018","unstructured":"Takayama KI, Suzuki T, Tanaka T, Fujimura T, Takahashi S, Urano T, et al. TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer. Oncogene. 2018;37:2165\u201380.","journal-title":"Oncogene"},{"key":"8140_CR45","doi-asserted-by":"publisher","first-page":"22321","DOI":"10.1002\/jcp.28798","volume":"234","author":"Q Han","year":"2019","unstructured":"Han Q, Cheng P, Yang H, Liang H, Lin F. Altered expression of microRNA-365 is related to the occurrence and development of non-small-cell lung cancer by inhibiting TRIM25 expression. J Cell Physiol. 2019;234:22321\u201330.","journal-title":"J Cell Physiol"},{"key":"8140_CR46","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.clbc.2020.12.001","volume":"21","author":"J Sato","year":"2021","unstructured":"Sato J, Azuma K, Kinowaki K, Ikeda K, Ogura T, Takazawa Y, et al. Combined Use of Immunoreactivities of RIG-I with Efp\/TRIM25 for predicting prognosis of patients with estrogen receptor-positive breast cancer. Clin Breast Cancer. 2021;21:399\u2013407.e2.","journal-title":"Clin Breast Cancer"},{"key":"8140_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/srep19070","volume":"6","author":"Z Zhu","year":"2016","unstructured":"Zhu Z, Wang Y, Zhang C, Yu S, Zhu Q, Hou K, et al. TRIM25 blockade by RNA interference inhibited migration and invasion of gastric cancer cells through TGF-\u03b2 signaling. Sci Rep. 2016;6:19070.","journal-title":"Sci Rep"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08140-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08140-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08140-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T16:02:35Z","timestamp":1764345755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08140-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8140"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08140-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in compliance with all relevant guidelines and regulations. This study was approved by Ethics Review Committees\/Institutional Review Boards of Central South University (Changsha, China). And all the animal experiments in this study were approved by the Institutional Animal Care and Use Committee (IACUC) of Central South University (Changsha, China) (Permit No. 2021-XMSB-0062). Clinical samples of breast cancer and normal breast samples were all collected from the Second Xiangya Hospital of Central South University. All patients involved in this article signed informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"872"}}